An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms POEM
- Sponsors Pfizer; ViiV Healthcare
- 28 Jun 2017 Planned End Date changed from 31 Oct 2018 to 26 Feb 2019.
- 28 Jun 2017 Planned primary completion date changed from 31 Oct 2018 to 26 Feb 2019.
- 17 May 2017 Planned End Date changed from 1 Oct 2018 to 31 Oct 2018.